The vaccine RSVpreF had an almost 82% efficacy against severe RSV infection in infants from birth through the first 90 days of life, according to company data.
Even if pediatric patients or their families have not traveled recently, they may still be at risk within a community where its members travel internationally and vaccination rates are low.